The mission of Emerging Markets is to develop bold, innovative partnerships so that Pfizer can reach billions of patients the company has never reached before. It targets diseases of the developing world and works to develop socially responsible, sustainable, and commercially viable health care solutions. Key regions include Brazil, China, India, and Russia, home to one-third of the world's population.
Primary Care Business Unit
With a strong heritage of success in developing many of the world's life-changing medicines, Primary Care has been at the heart of Pfizer's business for decades. Today, it is Pfizer's largest organization, operating globally in markets including the U.S., Europe, Canada, Korea, Japan, and Australia/New Zealand.
Movers in Primary Care are thought leaders in medicine, science, business, law, human resources, public affairs, and communications. Their diversity and commitment to advancing medicines and treatments are essential to the company's success. Their work ensures that, in the near future, Pfizer will have the medicines to affect millions of patients' lives, and the insights to transform healthcare.
Specialty and Oncology Business Unit
The Specialty Care and Oncology Business Unit aims to deliver extraordinary value in the treatment of serious conditions by focusing on meeting the distinct needs of patients, physicians, and payers. Science and customer insight will guide the Specialty team as it unlocks value in the current portfolio and expand Pfizer's opportunities to address physically and emotionally debilitating conditions.
Vaccines Business Unit
The Vaccines Business Unit currently focuses on infants and young children but will soon have a portfolio of products catering to patients of all ages. Its current portfolio consists of Prevenar, the leading and first-in-class pneumococcal conjugate vaccine in the world. The Vaccines business boasta of a strong pipeline consisting of a counterpart to Prevenar for adolescents and adults, as well as molecules in the fields of Alzheimer's Disease and Meningcococal serogroup B in adolescents.
Established Products Business Unit
Pfizer's Established Products Business Unit focuses on maximizing value for medicines that have lost or are close to losing patent exclusivity. It aims to provide underserved patients and payors in all parts of the world with affordable medicines characterized by Pfizer's reputation for quality, safety, and innovation. Its current portfolio is valued at approximately $11B and includes 380 products, covering a variety of therapeutic areas including Neurosciences, Cardiovascular disease, Women's Health, Antibiotics, Arthritis, and Pain.